The therapeutic and preventive effect of RRR-α-vitamin E succinate on prostate cancer via induction of insulin-like growth factor binding protein-3

Clinical Cancer Research

Volumn 13, Issue 7, 2007, Pages 2271-2280

  Yin, Yi ^a,b   Ni, Jing ^a   Chen, Ming ^a   DiMaggio, Matthew A ^a   Guo, Yinglu ^b   Yeh, Shuyuan ^a  

^a UNIVERSITY OF ROCHESTER   (United States)

^b PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL SUCCINATE; SMALL INTERFERING RNA; SOMATOMEDIN BINDING PROTEIN 3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN SYNTHESIS; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; MALE; MICE; MICE, NUDE; MICE, TRANSGENIC; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; VITAMIN E;

EID: 34247496688     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1217     Document Type: Article

References (49)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30.
2. Sung L, Greenberg ML, Koren G, et al. Vitamin E: the evidence for multiple roles in cancer. Nutr Cancer 2003;46:1-14.
3. Israel K, Yu W, Sanders BG, Kline K. Vitamin E succinate induces apoptosis in human prostate cancer cells: role for Fas in vitamin E succinate-triggered apoptosis. Nutr Cancer 2000;36:90-100.
4. Yu W, Israel K, Liao QY, et al. Vitamin E succinate (VES) induces Fas sensitivity in human breast cancer cells: role for M, 43,000 Fas in VES-triggered apoptosis. Cancer Res 1999;59:953-61.
5. Zhang Y, Ni J, Messing EM, et al. Vitamin E succinate inhibits the function of androgen receptor and the expression of prostate-specific antigen in prostate cancer cells. Proc Natl Acad Sci U S A 2002;99:7408-13.
6. Ni J, Chen M, Zhang Y, et al. Vitamin E succinate inhibits human prostate cancer cell growth via modulating cell cycle regulatory machinery. Biochem Biophys Res Commun 2003;300:357-63.
7. Venkateswaran V, Fleshner NE, Klotz LH. Modulation of cell proliferation and cell cycle regulators by vitamin E in human prostate carcinoma cell lines. J Urol 2002;168:1578-82.
8. Israel K, Sanders BG, Kline K. RRR-α-tocopheryl succinate inhibits the proliferation of human prostatic tumor cells with defective cell cycle/differentiation pathways. Nutr Cancer 1995;24:161-9.
9. Zhang M, Altuwaijri S, Yeh S. RRR-α-tocopheryl succinate inhibits human prostate cancer cell invasiveness. Oncogene 2004;23:3080-8.
10. Ni J, Wen X, Yao J, et al. Tocopherol-associated protein suppresses prostate cancer cell growth by inhibition of the phosphoinositide 3-kinase pathway. Cancer Res 2005;65:9807-16.
11. Ni J, Pang S, Yeh S. Different retention of α-vitamin E is correlated with its transporter gene expression and growth inhibition efficacy in prostate cancer cells. Prostate. Epub 2007; Jan 24.
12. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279:563-6.
13. Chan JM, Stampfer MJ, Ma J, et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 2002;94:1099-106.
14. Chen C, Lewis SK, Voigt L, et al. Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin. Cancer 2005;103:76-84.
15. Palmqvist R, Hallmans G, Rinaldi S, et al. Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in northern Sweden. Gut 2002;50:642-6.
16. Wakai K, Ito Y, Suzuki K, et al. Serum insulin-like growth factors, insulin-like growth factor-binding protein-3, and risk of lung cancer death: a case-control study nested in the Japan Collaborative Cohort (JACC) Study. Jpn J Cancer Res 2002;93:1279-86.
17. Gupta S, Hastak K, Ahmad N, Lewin JS, Mukhtar H. Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci U S A 2001;98:10350-5.
18. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002; 23:824-54.
19. Ali O, Cohen P, Lee KW. Epidemiology and biology of insulin-like growth factor binding protein-3 (IGFBP-3) as an anti-cancer molecule. Horm Metab Res 2003;35:726-33.
20. Silha JV, Sheppard PC, Mishra S, et al. Insulin-like growth factor (IGF) binding protein-3 attenuates prostate tumor growth by IGF-dependent and IGF-independent mechanisms. Endocrinology 2006;147:2112-21.
21. Greenberg NM, DeMayo F, Finegold MJ, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A 1995;92:3439-43.
22. Gupta S, Ahmad N, Marengo SR, et al. Chemoprevention of prostate carcinogenesis by α-difluoromethylornithine in TRAMP mice. Cancer Res 2000;60:5125-33.
23. Yeh S, Hu YC, Wang PH, et al. Abnormal mammary gland development and growth retardation in female mice and MCF7 breast cancer cells lacking androgen receptor. J Exp Med 2003;198:1899-908.
24. Shappell SB, Thomas GV, Roberts RL, et al. Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 2004;64:2270-305.
25. Gupta S, Adhami VM, Subbarayan M, et al. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 2004;64:3334-43.
26. Takaoka M, Harada H, Andl CD, et al. Epidermal growth factor receptor regulates aberrant expression of insulin-like growth factor-binding protein 3. Cancer Res 2004;64:7711-23.
27. Lee HY, Chun KH, Liu B, et al. Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer. Cancer Res 2002;62:3530-7.
28. Yu W, Sanders BG, Kline K. RRR-α-tocopheryl succinate-induced apoptosis of human breast cancer cells involves Bax translocation to mitochondria. Cancer Res 2003;63:2483-91.
29. Kaplan-Lefko PJ, Chen TM, Ittmann MM, et al. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 2003;55:219-37.
30. Kawada M, Inoue H, Masuda T, Ikeda D. Insulin-like growth factor I secreted from prostate stromal cells mediates tumor-stromal cell interactions of prostate cancer. Cancer Res 2006;66:4419-25.
31. Kaicer EK, Blat C, Harel L. IGF-I and IGF-binding proteins: stimulatory and inhibitory factors secreted by human prostatic adenocarcinoma cells. Growth Factors 1991;4:231-7.
32. Renehan AG, Zwahlen M, Minder C, et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004;363:1346-53.
33. Liu B, Lee KW, Li H, et al. Combination therapy of insulin-like growth factor binding protein-3 and retinoid X receptor ligands synergize on prostate cancer cell apoptosis in vitro and in vivo. Clin Cancer Res 2005;11:4851-6.
34. Singh RP, Dhanalakshmi S, Tyagi AK, et al. Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels. Cancer Res 2002;62:3063-9.
35. Boyle BJ, Zhao XY, Cohen P, Feldman D. Insulin-like growth factor binding protein-3 mediates 1 α,25-dihydroxyvitamin d(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. J Urol 2001;165:1319-24.
36. Singh RP, Tyagi AK, Dhanalakshmi S, Agarwal R, Agarwal C. Grape seed extract inhibits advanced human prostate tumor growth and angiogenesis and upregulates insulin-like growth factor binding protein-3. Int J Cancer 2004;108:733-40.
37. Shukla S, Mishra A, Fu P, et al. Up-regulation of insulin-like growth factor binding protein-3 by apigenin leads to growth inhibition and apoptosis of 22Rv1 xenograft in athymic nude mice. FASEB J 2005;19:2042-4.
38. Rajah R, Lee KW, Cohen P. Insulin-like growth factor binding protein-3 mediates tumor necrosis factor-α-induced apoptosis: role of Bcl-2 phosphorylation. Cell Growth Differ 2002;13:163-71.
39. Hwa V, Oh Y, Rosenfeld RG. Insulin-like growth factor binding protein-3 and -5 are regulated by transforming growth factor-13 and retinoic acid in the human prostate adenocarcinoma cell line PC-3. Endocrine 1997;6:235-42.
40. Gucev ZS, Oh Y, Kelley KM, Rosenfeld RG. Insulin-like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor β2-induced growth inhibition in human breast cancer cells. Cancer Res 1996;56:1545-50.
41. Grimberg A, Liu B, Bannerman P, El-Deiry WS, Cohen P. IGFBP-3 mediates p53-induced apoptosis during serum starvation. Int J Oncol 2002;21:327-35.
42. Venkateswaran V, Fleshner NE, Sugar LM, Klotz LH. Antioxidants block prostate cancer in lady transgenic mice. Cancer Res 2004;64:5891-6.
43. Andreasen MF, Kroon PA, Williamson G, Garcia-Conesa MT. Intestinal release and uptake of phenolic antioxidant diferulic acids. Free Radic Biol Med 2001;31:304-14.
44. Andreasen MF, Kroon PA, Williamson G, Garcia-Conesa MT. Esterase activity able to hydrolyze dietary antioxidant hydroxycinnamates is distributed along the intestine of mammals. J Agric Food Chem 2001;49:5679-84.
45. Gupta S. Prostate cancer chemoprevention: models, limitations, and potential [review]. Int J Oncol 2004;25:1133-48.
46. Kelloff GJ, Lieberman R, Brawer MK, et al. Strategies for chemoprevention of prostate cancer. Prostate Cancer Prostatic Dis 1999;2:27-33.
47. Mentor-Marcel R, Lamartiniere CA, Eltoum IE, Greenberg NM, Elgavish A. Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). Cancer Res 2001;61:6777-82.
48. Raghow S, Hooshdaran MZ, Katiyar S, Steiner MS. Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Cancer Res 2002;62:1370-6.
49. Raghow S, Kuliyev E, Steakley M, Greenberg N, Steiner MS. Efficacious chemoprevention of primary prostate cancer by flutamide in an autochthonous transgenic model. Cancer Res 2000;60:4093-7.